GLP-1 Receptor Agonist Shows Joint Protection in Obesity-Induced Osteoarthritis Mouse Model

A new study shows that semaglutide mitigates osteoarthritis progression in an obesity-induced mouse model through mechanisms independent of weight loss. The research, published in Cell Metabolism, demonstrates that the glucagon-like peptide-1 receptor agonist provides joint protection through chondrocyte metabolic reprogramming.

Investigators fed mice a high-fat diet until their body weight exceeded that of regular-diet controls by more than 20 percent, after which they performed destabilization of the medial meniscus surgery to induce osteoarthritis. One group subsequently received weekly subcutaneous semaglutide injections. Osteoarthritis severity and treatment efficacy were assessed using micro-CT imaging, histological analyses and pain-related behavioral tests between 6 and 12 weeks post-surgery.

Obese mice treated with semaglutide exhibited reduced osteoarthritis pathology, including less cartilage degeneration, osteophyte formation, synovial abnormalities and pain sensitivity compared with untreated obese controls. The benefits were independent of weight loss and instead arose from chondrocyte metabolic reprogramming via the GLP-1R–AMPK–PFKFB3 axis, supporting cartilage restoration.

Although age is considered the primary risk factor for osteoarthritis, increasing epidemiological and clinical evidence indicates that metabolic dysfunction, particularly insulin resistance, also contributes to osteoarthritis onset and progression. Over the past two decades, glucagon-like peptide-1 receptor agonists such as semaglutide, which mimic endogenous incretin signaling, have become widely used to treat obesity and promote weight loss.

This work highlights the potential protective effect of semaglutide on joint health, warranting clinical validation.